Antiplatelet Drug Resistance and Variability in Response: The Role of Antiplatelet Therapy Monitoring

This publication has 156 references indexed in Scilit:

• Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response
  Clinical Pharmacology & Therapeutics, 2011
• Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy
  Clinical Pharmacology & Therapeutics, 2011
• The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy
  American Heart Journal, 2011
• Effects ofCYP2C19Genotype on Outcomes of Clopidogrel Treatment
  New England Journal of Medicine, 2010
• Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI
  JAMA, 2010
• Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
  The Lancet, 2010
• Adenosine diphosphate–induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events
  American Heart Journal, 2010
• Association of Cytochrome P450 2C19 Genotype With the Antiplatelet Effect and Clinical Efficacy of Clopidogrel Therapy
  JAMA, 2009
• Interaction Between Cigarette Smoking and Clinical Benefit of Clopidogrel
  JACC, 2009
• Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
  New England Journal of Medicine, 2009